Clinical Trial

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Study acronym: ASPIRIN
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-06-15; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2024-11-04
Trial Details
NCT Number NCT06468202
Lead Sponsor Ohio State University
Collaborators: Patient-Centered Outcomes Research Institute, Northwestern University, Preeclampsia Foundation
Conditions Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Enrollment 10,742 participants
Start Date 2024-10-18
Primary Completion 2029-01-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-04